CURATIS – A specialty pharmaceutical company focused on (ultra) rare diseases

26 April 2024

CURATIS
Innovative Specialist Medicines

Vision: To become a leading European Specialist Medicines Company

by focusing on the acquisition, development and commercialization of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases

CURATIS
Innovative Specialist Medicines

Background

- Curatis Group, formed by the business combination of Curatis Holding AG (formerly Kinarus Therapeutics Holding AG) and Curatis AG, is a Swiss-based specialty pharmaceutical company
- Distribution Business activity
  - >30 medicines
  - Revenue generating and profitable
- Development Business activity
  - C-PTBE-01 for the treatment of peritumoral brain edema in pediatric patients – next major development step: pivotal clinical study
  - C-AM-01 for the prevention of severe migraine with aura – next major development step: clinical phase IIb study
  - C-MOH-01 for the treatment and prevention of medication overuse headache – next major development step: clinical phase IIb study
  - KIN001 for the treatment of rare inflammatory and fibrotic diseases (e.g. Idiopathic Pulmonary Fibrosis) – next major development step: clinical proof-of-concept



Investment Case

- Experienced board and management team with track record in development and commercialization of orphan drug products

- Balanced, lower risk business model with a mix of medicines distribution and drug development activities
- Focus is on (ultra) orphan indications

- CHF4.4m cash raised in the context of the Business Combination

- Promising set of development projects with existing safety and efficacy data

- Significant value creation potential with strong development pipeline, enriched with KIN001
- Potential for rare pediatric disease voucher

- KIN001 to be evaluated for ultra-orphan indications
- IPF project aligned with the strategic focus on orphan indications

- Significant market potential for all product candidates
- Expected orphan drug market growth at CAGR of 11.6% from USD 173bn (2023E) to USD 300bn (2028E)

- High unmet medical need
- Small target audience
- Lower funding requirements expected



Speciality Medicines Distribution Business Strategy

Distribution of third-party products focused on rare and specialty care diseases

Cash Flow Generating Base Business

- The base business of Curatis is a Swiss specialist medicines distribution business, whereby Curatis is exclusive distributor for currently over 30 medicines in Switzerland
- Curatis aims at significantly increasing the number of third-party medicines for distribution under contract in Switzerland
- Curatis aims at securing rights to distribution products for Europe
- In the mid to long-term Curatis is expected to have its own products when its development projects receive regulatory approval



Examples of Products Distributed		
Product	**Type**	**Indication**
Cuprior®	Rare disease	Morbus Wilson
elmiron®	Rare disease	Bladder pain syndrom
Xenazine®	Rare disease	Huntington disease
Nityr®	Rare disease	Hereditary tyrosinemia type 1
Zonegran®	Specialty care	Epilepsy

Geographic Expansion of Distribution

- Curatis distribution business currently focused on Switzerland
- With increased visibility and greater access to funding that is associated with a public company, Curatis is aiming to set-up its own affiliates in the following European countries:

  - Germany
  - France
  - UK
  - Italy

Development Pipeline

Indication	Project	Development stage
Peritumoral Brain Edema in children	C-PTBE-01	
Migraine with Aura	C-AM-01	
Medication Overuse Headache	C-MOH-01	
Various inflammatory and fibrotic diseases (e.g., Idiopathic Pulmonary Fibrosis)	KIN001	



A. C-PTBE-01: Peritumoral Brain Edema in Children

- Peritumoral brain edema (PTBE) in children
  - Focus on malignant brain tumors in children (initially on Diffuse Intrinsic Pontine Glioma DIPG)
  - Tumor induced edema (PTBE) is a severe complication where no curative therapy is available
  - Average survival time after diagnosis: 9 months, main treatment goal: quality of life
  - Key adjuvant therapy in PTBE are corticosteroids, sometimes in combination with Avastin (bevacizumab); however, steroids may have severe cardiovascular, muscular, and psychiatric side effects (accentuated in pediatric patients)
  - C-PTBE-01 has shown a strong steroid sparing effect which might allow a significant reduction of steroid usage
- Phase I, II and III clinical data available
  - 1 pivotal study with a relatively small patient number is envisaged for registration
- Peak sales potential: approx. US$ 250 million
  - Approx. 150-300 patients in the US, similar numbers in Europe
- Intellectual property position
  - USA: orphan drug protection 7 years, EU: orphan drug protection 10 years
- Rare Pediatric Disease Voucher may be granted if rare pediatric disease designation and market approval are granted
  - A Rare Pediatric Disease Voucher allows for priority review within 6 months and thus can significantly shorten time to approval / commercialization for any applicant (Rare Pediatric Disease Priority Review Voucher Program runs out in September 2024, historically was renewed)
  - Rare Pediatric Disease Vouchers can be sold from sponsor to third parties for priority review of any product candidate under certain circumstances

Next steps:

- **Scientific advice meeting with FDA / EMA**
- **Preparation of pivotal study with envisaged start in 2025**

B. C-AM-01: Migraine with Aura

- Migraine with Aura
  - Migraine Auras are the sensory symptoms (neurologic, gastrointestinal, and autonomic) that can occur before or during a migraine episode
  - Symptoms can include flashes of light, blind spots, or tingling in the hands or face, may look like a more serious condition, such as a stroke or a seizure and are comparable to epileptic attacks
  - Migraine with Aura can cause significant disability on patients and compromise their daily life activity
- High unmet medical need
  - No approved specific preventive treatment for Migraines with Aura
- Two Phase IIa clinical proof-of-concept studies suggest reduction of number of auras
- Peak sales potential: approx. US$ 500m
  - Migraine prevalence is approx. 15-20% of total population
  - Approx. 15-30% of migraine patients experience aura symptoms
  - Curatis focuses on severe cases
- Intellectual property position
  - USA: Use and dosage regimen patent granted in Nov 2021 based on study results
  - EU: 10 years data exclusivity and market protection

Next steps:

- **Preparation of clinical phase IIb dose finding study**
- **Partnering**

C. C-MOH-01: Medication Overuse Headache

- Headache characterized by worsening as result from medication overuse
  - Frequent and prolonged use of medication for the acute treatment
  - Paradoxical effect: Analgesic medication increase headache frequency/intensity
  - Treatment of choice is discontinuation of the overused medication, often associated with acute headaches and withdrawal symptoms
- Very high unmet medical need
  - No approved drug for treatment/prevention of MOH based on tension type headache (TTH)
  - High relapse rate
- Phase IIa clinical proof-of-concept study in chronic tension type headache available
- Peak sales potential: approx. US$ 500million
  - Approx. 14 million patients in US & EU
  - Potential expansion to chronic TTH
- Intellectual property position
  - USA: Use patent granted in Dec 2021
  - EU: 10-year data exclusivity and market protection

Next steps:

- **Preparation of clinical phase IIb dose finding study**
- **Partnering**

D. KIN001: ultra-orphan inflammatory and fibrotic diseases

KIN001

- Proprietary compound combination with potential in inflammatory and fibrotic diseases

Evaluation of KIN001 for very rare diseases (ultra-orphan indications)

- Screening of potential inflammatory and fibrotic orphan and ultra orphan indications for the KIN001 combination

KIN001 for treatment of Idiopathic Pulmonary Fibrosis (IPF)

- Scientific rationale
  - IPF is a rare progressive illness (orphan disease) of the respiratory system with chronic scarring of lung tissue
  - Symptoms include gradual onset of shortness of breath and dry cough, complications include pulmonary hypertension, heart failure, pneumonia or pulmonary embolism
  - KIN001 has shown beneficial effects in reducing IPF in a well-characterised animal model of IPF
- Very high unmet medical need
  - Incidence of 13-20 patients per 100,000 people annually, average life expectancy after diagnosis is about 4 years
  - Current treatments are used to slow progression, no treatment to reverse lung scarring available
- Intellectual property position
  - Patent protection and data protection
  - Orphan drug protection may be possible

Next steps:

- **Evaluation for potential orphan and ultra-orphan indications**
- **Potential partnering for IPF**

Source: NIH

Development Roadmap

Various potentially significant value inflection points



Board of Directors and Executive Management Team

Board of Directors

Dr. Marian Borovsky

- Non-Executive Chairman of the Board of Directors
- Former Group General Counsel of Actelion

Günter Graubach

- Founder and Executive Member of the Board of Directors
- Previously Roche, Santhera

Dr. Silvio Inderbitzin

- Non-Executive Member of the Board of Directors
- Former CEO of Spirig

Dr. Roland Rutschmann

- Executive Member of the Board of Directors
- Previously Roche, Actelion, Recordati (Orphan Europe)

Executive Management Team

Dr. Roland Rutschmann

- CEO

Günter Graubach

- CCDO (Chief Corporate Development Officer)

François Bersier

- COO

Highlights

Cash flow generating distribution business activity

- Historically profitable distribution business activity
- Track record of winning new contracts to grow the distribution business activity
- Expansion into EU planned, contract and product screening ongoing

Promising project pipeline

- Focus on orphan / ultra-orphan and specialty care indications with high unmet medical need
- Niche market segments with lower competitive pressures and lower need for sales force
- Focus on compounds with known safety, efficacy and production profile to limit development risk
- Large market potential for all product candidates as well as partnering options
- Late development phase portfolio with lead product C-PTBE-01

Near term value triggers

- Scientific advice meetings with FDA / EMA planned in 2024 / 2025
- Initiation of pivotal study for C-PTBE-01 planned for 2025
- Partnering discussions for all product candidates planned, which may lead, subject to its success, to potential milestone payments

Experienced management team

- Experience in orphan drug market and leading roles with companies such as Roche, Actelion, Orphan Europe (Recordati Rare Diseases) and Santhera
- Track record in development and sale of specialty care medicinal products (Haemopressin (terlipressin))
- Well known international scientific and medical advisors

Important Notice

THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF SWISS FINANCIAL SERVICES ACT ("FINSA"), NOR A PROSPECTUS UNDER ANY OTHER APPLICABLE LAWS AND SHOULD NOT BE TREATED AS OFFERING MATERIALS OF ANY SORT AND IS FOR INFORMATION PURPOSES ONLY. THE INFORMATION CONTAINED HEREIN IS IN SUMMARY FORM AND MUST BE CONSIDERED IN CONJUCTION WITH AND SUBJECT TO THE PUBLICLY AVAILABLE INFORMATION OF CURATIS HOLDING AG. THIS DOCUMENT IS BEING FURNISHED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, REDISTRIBUTED OR MADE AVAILABLE IN WHOLE OR IN PART TO ANY OTHER PERSON OR ANY PURPOSE, WITHOUT THE PRIOR WRITTEN CONSENT OF CURATIS HOLDING AG. THIS DOCUMENT CONSTITUTES ADVERTISMENT WITHIN THE MEANING OF ARTICLE 68 OF THE FINSA.

This document contains certain forward-looking statements. Other written materials, as well as other written and oral statements made to the public, may also contain forward-looking statements. Forward-looking statements can be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," "may," "could," "would," "anticipate," "seek," or similar terms, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Curatis Holding AG, of any of the transactions described; or regarding potential future sales or earnings of the group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.

This document is not an offering circular or prospectus and is being furnished to you solely for your information and may not be reproduced, redistributed or made available in whole or in part to any other person for any purpose, without the prior consent of Curatis Holding AG. This document is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy, any security nor is it a recommendation to buy or sell any security. Any decision to subscribe to any securities should only be made on the basis of an independent review by you of Curatis Holding AG publicly available information. Curatis Holding AG does not accept any liability arising from the use of, or make any representation as to the accuracy or completeness of, this document or the publicly available information on Curatis Holding AG. We provide the information in this document as of the date hereof and the information contained in this document is subject to change at any time. We do not intend, and do not assume any obligation, to update any information or forward-looking statements set out in this document as a result of new information, future events or otherwise. Curatis Holding AG shall not be responsible for, or for investigating, any matter which is the subject of any statement, representation, warranty or covenant of Curatis Holding AG contained in any agreement or document relating to a transaction (including to the Business Combination with Curatis AG announced with a media release on 29 January 2024), or for the execution, legality, effectiveness, adequacy, genuineness, validity, enforceability or admissibility in evidence thereof. This document is not for distribution, directly or indirectly in or into the United States (as defined in Regulation S under the US Securities Act of 1933, as amended ("US Securities Act")). This document is not an offer to sell securities, or the solicitation of any offer to buy securities, nor shall there be any offer of securities in any jurisdiction in which such offer or sale would be unlawful. The securities mentioned in this document have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States absent registration or exemption from registration under the US Securities Act. There will be no public offer of the securities in the United States or in any other jurisdiction. In connection with the Business Combination there has not been, nor will there be, any public offering of any securities in any jurisdiction in and outside of Switzerland. The securities in connection with the Business Combination may not be offered to the public in any jurisdiction in circumstances which would require Curatis AG or Curatis Holding AG to prepare or register any prospectus or offering document relating to the securities in connection with the Business Combination in such jurisdiction. No action has been taken or will be taken in any jurisdiction outside of Switzerland by Curatis AG and Curatis Holding AG that would, or is intended to, permit a public offering of the securities in connection with the Business Combination in such jurisdiction.


CURATIS
Innovative Specialist Medicines